W
Wanjuan Yang
Researcher at Wellcome Trust Sanger Institute
Publications - 8
Citations - 4829
Wanjuan Yang is an academic researcher from Wellcome Trust Sanger Institute. The author has contributed to research in topics: Cancer & Biomarker discovery. The author has an hindex of 6, co-authored 6 publications receiving 3384 citations. Previous affiliations of Wanjuan Yang include Howard Hughes Medical Institute.
Papers
More filters
Journal ArticleDOI
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett,Elena J. Edelman,Sonja J. Heidorn,Christopher Greenman,Christopher Greenman,Anahita Dastur,King Wai Lau,Patricia Greninger,I. Richard Thompson,Xi Luo,Jorge Soares,Qingsong Liu,Francesco Iorio,Francesco Iorio,Didier Surdez,Li Chen,Randy J. Milano,Graham R. Bignell,Ah Ting Tam,Helen Davies,Jesse A. Stevenson,Syd Barthorpe,Stephen R. Lutz,Fiona Kogera,Karl P. Lawrence,Anne McLaren-Douglas,Xeni Mitropoulos,Tatiana Mironenko,Helen Thi,Laura Richardson,Wenjun Zhou,F Jewitt,Tinghu Zhang,Patrick O’Brien,Jessica L. Boisvert,Stacey Price,Wooyoung Hur,Wanjuan Yang,Xianming Deng,Adam Butler,Hwan Geun Choi,Jae Won Chang,José Baselga,Ivan Stamenkovic,Jeffrey A. Engelman,Sreenath V. Sharma,Sreenath V. Sharma,Olivier Delattre,Julio Saez-Rodriguez,Nathanael S. Gray,Jeffrey Settleman,P. Andrew Futreal,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Sridhar Ramaswamy,Ultan McDermott,Cyril H. Benes +57 more
TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Journal ArticleDOI
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells
Wanjuan Yang,Jorge Soares,Patricia Greninger,Elena J. Edelman,Howard Lightfoot,Simon A. Forbes,Nidhi Bindal,Dave Beare,James Smith,I. Richard Thompson,Sridhar Ramaswamy,P. Andrew Futreal,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Ultan McDermott,Mathew J. Garnett +16 more
TL;DR: The Genomics of Drug Sensitivity in Cancer (GDSC) provides a unique resource incorporating large drug sensitivity and genomic datasets to facilitate the discovery of new therapeutic biomarkers for cancer therapies.
Proceedings ArticleDOI
Abstract 2206: Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells.
Wanjuan Yang,Jorge Soares,Patricia Greninger,Elena J. Edelman,Howard Lightfoot,Simon A. Forbes,Ramaswamy Sridhar,P. Andrew Futreal,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Ultan McDermott,Mathew J. Garnett +12 more
TL;DR: This work is using pharmacogenomic profiling in cancer cell lines as a biomarker discovery platform by systematically linking pharmacological data with genomic information in cancer cells to facilitate discovery of new therapeutic biomarkers for cancer therapies.
Journal ArticleDOI
Cell Model Passports—a hub for clinical, genetic and functional datasets of preclinical cancer models
Dieudonne van der Meer,Syd Barthorpe,Wanjuan Yang,Howard Lightfoot,Caitlin Hall,James G. R. Gilbert,Hayley E. Francies,Mathew J. Garnett +7 more
TL;DR: The Cell Model Passports are a valuable tool enabling access to high-dimensional genomic and phenotypic cancer cell model datasets empowering diverse research applications.
Journal ArticleDOI
Effective drug combinations in breast, colon and pancreatic cancer cells
Patricia Jaaks,Elizabeth A. Coker,Daniel J. Vis,Olivia Edwards,Emma F. Carpenter,Simonetta Maria Leto,Lisa Dwane,Francesco Sassi,Howard Lightfoot,Syd Barthorpe,Dieudonne van der Meer,Wanjuan Yang,Alexandra Beck,Tatiana Mironenko,Caitlin Hall,James Hall,Iman Mali,Laura Richardson,Charlotte Tolley,James Morris,Frances Thomas,Ermira Lleshi,Nanne Aben,Cyril H. Benes,Andrea Bertotti,Livio Trusolino,Lodewyk F. A. Wessels,Mathew J. Garnett +27 more
TL;DR: In this paper , the potency and efficacy of 2,025 clinically relevant two-drug combinations were evaluated, generating a dataset encompassing 125 molecularly characterized breast, colorectal and pancreatic cancer cell lines.